Jayne Franklyn qualified MBChB with Honours from the University of Birmingham in 1979, having been awarded the Queen’s Scholarship in 1978 and the Arthur Foxwell Memorial Prize for Clinical Medicine in 1979. She completed basic training in medicine, obtaining MRCP (UK) and then undertook a period of research as Sheldon Clinical Fellow and MRC Training Fellow, in the Department of Medicine in Birmingham, proceeding to MD and then PhD. She subsequently became Wellcome Trust Senior Clinical Fellow in 1988 and was promoted to Reader in 1993 and to Professor of Medicine in 1995. She became Head of the Department of Medicine in 2007 and was Associate Dean for the Graduate School from 2002-2008 before being appointed as Head of the School of Clinical and Experimental Medicine in 2008. She was conferred with the title of William Withering Chair of Medicine in 2011.
She has longstanding laboratory and clinical research interests focussing on the pathogenesis and long term consequences of thyroid cancer and autoimmune thyroid disease. Her work, and that of her team, has contributed significantly to our understanding of how best to treat thyroid disorders and to prevent their complications. She has been an active contributor to national and international guidelines for best practice. In recognition of her research contributions she was elected Fellow of the Academy of Medical Sciences in 2000 and has been awarded the Royal College of Physicians Goulstonian Lectureship, as well as Plenary Lectureships of the Society for Endocrinology, Clinical Endocrinology Trust, the International Congress of Endocrinology, the Endocrine Society of Australia and both Keynote and Paul Starr Lectureships of the American Thyroid Association. In 2012 she will deliver the Pitt Rivers Lectureship of the British Thyroid Association and Society for Endocrinology.
Boelaert K, Torlinska B, Holder RL, Franklyn JA (2010) Older subjects with hyperthyroidism present with a paucity of symptoms and signs 1 – a large cross-sectional study Journal of Clinical Endocrinology and Metabolism 95, 2715-26
Watkins R, Read ML, Smith VE, Sharma N, Reynolds GM, Buckley L, Doig C, Campbell MJ, Lewy G, Eggo MC, Loubiere LS, Franklyn JA, Boelaert K, McCabe CJ (2010) Pituitary tumor transforming gene – a novel gene in breast cancer. Cancer Research 70, 3739-49
Newby PR, Pickles OJ, Mazumdar S, Brand OJ, Carr-Smith JD, Pearce SHS, Franklyn JA, WTCCC, Evans DM, Simmonds MJ, Gough SCL (2010) Follow-up of potential novel Graves’ susceptibility loci, identified in the UK WTCCC genome-wide non-synonymous SNP study. European Journal of Human Genetics 18, 1021-6
Vasilopoulou E, Loubiere LS, McCabe CJ, Franklyn JA, Kilby MD, Chan SY (2010) Differential T3 responsiveness and transport by human cytotrophoblasts from normal and growth-restricted pregnancies Journal of Clinical Endocrinology and Metabolism 95, 4762-70
Simmonds MJ, Brand OJ, Barrett JC, Newby PR, Franklyn JA, Gough SC (2010) Association of FCRL5 with Graves’ disease is secondary to the effect of FCRL3. Clinical Endocrinology 73, 654-60
Rodondi N, den Elzen WPJ, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump M, Newman AB, Cornuz J, Franklyn JA, Westendorp RGJ, Vittinghoff E, Gussekloo J (2010) Subclinical hypothyroidism and the risk of coronary disease and mortality. Journal of the American Medical Association 304, 1365-1374
PłoskiR, BrandOJ, Franaszczyk M,Jurecka-LubienieckaB, Kula D, Krajewski P, KaramatMA, Simmonds MJ, FranklynJA, Gough SC, JarząbB, Bednarczuk T (2010)Variants in the first intron of the thyroid stimulating hormone receptor (TSHR) gene are major risk factors for Graves’ disease in three European Caucasian cohorts. PLoS One. 2010 Nov 25;5(11):e15512.
Thangaratinam S, TanA, Knox E, Kilby MD, FranklynJA, Coomarasamy A (2011) Miscarriage rate is tripled in women with thyroid auto-antibodies: A meta-analysis of evidence British Medical Journal (in press)